AAN 2022 | Retinal atrophy as a biomarker in multiple sclerosis

Christian Cordano, MD, PhD, UCSF Weill Institute for Neurosciences, San Francisco, CA, explains the use of retinal atrophy as a biomarker in multiple sclerosis (MS). In particular, changes in the inner nuclear layer (INL) are used as a measure of inflammation and aid in quantifying different aspects throughout the MS disease course. Dr Cordano highlights that studies have shown INL thickening to correlate with inflammation and later become a biomarker of neurodegeneration in disease progression. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.